Finding advances search for cure other than liver transplantation
A protein modified to increase the amount of time it circulates in the bloodstream appears to reverse liver fibrosis and cirrhosis in rats, according to results of a study led by Johns Hopkins researchers.
The investigators say the findings, reported ahead of print in the March 3 early view edition of Hepatology, advance the search for a potential cure for the thousands of patients worldwide living with these incurable diseases. At present, there is little effective treatment and no cure other than liver transplantation, which carries its own risks and often fails.
“Our findings demonstrate that the damaging effects of liver cirrhosis in laboratory rats can be effectively treated, and perhaps even reversed, using a protein therapeutic that has been modified to enhance its activity through site-specific conjugation of a polymer that greatly enhances its residence time in the body,” says senior author Justin Hanes, Ph.D., director of the Center for Nanomedicine at the Wilmer Eye Institute at Johns Hopkins. “This approach has tremendous potential to help people with this devastating condition and may also be helpful to the millions of patients with other diseases where fibrosis plays an important role.”
Liver fibrosis and its more severe form, cirrhosis, are caused by scar tissue that forms in the liver that is usually induced by chronic alcohol abuse, infections and autoimmune diseases. The progressive stiffening of the liver, a hallmark of the disorders, occurs when a type of liver cell known as the hepatic stellate cell is “activated” and overproduces the stringy network of proteins called the extracellular matrix that binds cells together.
Being able to turn cirrhosis around, especially in its late stages, would be a great boon, says Seulki Lee, Ph.D., assistant professor in the Department of Radiology and Radiological Science at the Johns Hopkins University School of Medicine. “That’s because liver fibrosis and cirrhosis can be asymptomatic for decades,” Lee says. “Many patients only seek treatment when their disease becomes very advanced, at which point liver transplant is their only option.”
Lee cautions, however, that his team’s work is years from any possible application to patients.
Scientists have known for more than a decade that a protein called tumor necrosis factor-related apoptosis-inducing ligand — TRAIL, for short — can specifically kill activated hepatic stellate cells that overproduce the extracellular matrix, sparing healthy cells in the liver. However, Lee explains, TRAIL has thus far proven unsuccessful for clinical use because in animal studies, enzymes in the bloodstream quickly degrade it before it has time to work.
Seeking a way to extend TRAIL’s half-life, or the time that it remains intact in the bloodstream, Lee and his colleagues coated TRAIL with polyethylene glycol (PEG), a synthetic polymer that’s widely used as a preservative, lubricant and ingredient in skin creams, and is already being used to extend the bloodstream life of a handful of drugs that treat neutropenia, hemophilia and rheumatoid arthritis.
Lee says initial experiments showed that this “PEGylated” TRAIL had a half-life of between eight and nine hours in monkeys, compared to less than 30 minutes for the unmodified protein. When the scientists intravenously dosed rats that had liver fibrosis with the modified TRAIL for 10 days, the animals’ activated hepatic stellate cells died off. By fighting these bad cells, signs of fibrosis began to diminish. Further investigation showed that multiple genes associated with fibrosis had reduced activity, and the proteins produced by these genes faded away.
Findings were similar in rats with advanced cirrhosis, Lee says. Additionally, when the researchers examined the rodents’ liver tissue under a microscope, they found that animals treated with PEGylated TRAIL had fewer deposits of collagen and other extracellular matrix proteins, offering some evidence that the disease had actually been reversed.
Further experiments showed that PEGylated TRAIL selectively killed human-activated hepatic stellate cells growing in petri dishes while leaving normal liver cells unharmed, suggesting that findings in these animal models could apply to damaged human livers with limited toxicity concerns.
Lee says the research team hopes to develop PEGylated TRAIL for clinical trials in human patients in the next two years. He adds that some preliminary data suggest that the modified protein could also treat other fibrotic diseases as well, such as pancreatic or lung fibrosis, which also have no effective treatment.
“Eventually,” Lee says, “we might be able to develop PEGylated TRAIL into a universal anti-fibrotic agent that can treat many different conditions.”
Learn more: Modified protein reverses cirrhosis in lab rats
The Latest on: Protein therapeutic
[google_news title=”” keyword=”Protein therapeutic” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Protein therapeutic
- Acrivon Therapeutics: Strong Buy on Promising Clinical Trials and Innovative Drug Developmenton March 28, 2024 at 11:07 am
TD Cowen analyst Marc Frahm has maintained their bullish stance on ACRV stock, giving a Buy rating today. Marc Frahm has given his Buy rating ...
- Denali Therapeutics gets grant for proteins for treating sanfilippo syndrome Aon March 28, 2024 at 6:16 am
Discover how Denali Therapeutics' patented proteins can revolutionize the treatment of Sanfilippo syndrome A by crossing the blood-brain barrier with enhanced efficiency. Explore the groundbreaking ...
- New AI-Based Protein Prediction Method Revolutionizing Drug Discoveryon March 28, 2024 at 12:19 am
Researchers have found a novel AI-based protein prediction technique that might completely change the drug development industry. Using AlphaFold 2’s capabilities, this novel approach—created by PhD ...
- Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activityon March 27, 2024 at 2:15 pm
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s ...
- Team assesses biological functions, diseases and therapeutic targets of heat shock protein 90on March 26, 2024 at 1:58 pm
A review titled "Heat shock protein 90: biological functions, diseases, and therapeutic targets" and published in MedComm, conceived by Dr. Guiqin Hou, has been written by her graduate students Huiyun ...
- Researchers identify protein sensor that plays a role in lung fibrosison March 26, 2024 at 12:51 pm
Researchers at Weill Cornell Medicine have discovered a protein called SEL1L that plays a critical role in clearing collagen from tissue, and that may be a therapeutic target to help prevent fibrosis, ...
- Arcturus Therapeutics files patent for modified human otc protein for treating OTC deficiencyon March 26, 2024 at 5:43 am
Discover how Arcturus Therapeutics' patent for a modified human OTC protein revolutionizes OTC deficiency treatment with codon optimized mRNA sequences.
- Protein in human sweat could be friend or foe with Lyme diseaseon March 24, 2024 at 6:28 pm
An international team of researchers say a protein found in human sweat may help protect people from Lyme disease, a tick-borne illness that affects nearly a half-million people every year in the U.S.
- A protein in human sweat may cure Lyme diseaseon March 24, 2024 at 3:48 am
Scientists believe a skin cream made of sweat protein may provide relief to Lyme disease patients for whom antibiotics don't work.
- A protein in human sweat protects against Lyme disease, study findson March 21, 2024 at 9:42 am
Lyme disease impacts more than half a million Americans every year. The new research could help develop treatments ...
via Bing News